All In Biotech

Drug Trial Radar · NCT03515538

Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers

A Phase 2a Randomized, Parallel Group, Open Label, Multicenter Study to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx

Last checked: Nov 19, 2026Latest source record: Nov 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

53

Actual

Start

Jul 12, 2018

Primary completion

Oct 22, 2019

Study completion Oct 8, 2020

Sponsor

Lead sponsor
EpicentRx, Inc.Industry
Sponsor type
Industry
Collaborators
Prothex, Inc.
First posted
May 3, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Supportive care
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the duration or length of severe oral mucositis in patients with head and neck cancers. All patients in this study will receive 7 weeks of standard of care radiation therapy given with the chemotherapy agent, cisplatin. Patients in arms 1, 2 and 3 will also receive RRx-001 on different schedules.

Conditions

  • Oral Mucositis

Interventions

  • RRx-001Drug

    RRx-001 for injection

  • Cisplatin for injectionDrug

    Patients will receive 3 doses of cisplatin at 100 mg/m2 in accordance with applicable guidelines such as NCCN; however, these guidelines are not intended to supersede or replace institutional guidelines with respect to appropriate and necessary care for individual patients

  • Radiation TherapyRadiation

    Intensity Modulated Radiation Therapy (IMRT) in accordance with the American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for IMRT) is mandatory for this study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Duration of Severe Oral Mucositis (SOM)Time frame: From start of treatment through 28 days post treatment for up to 11 weeks from Start of Treatment

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • John Wayne Cancer Institute @ Providence St. John's Health Center

    Santa Monica, California

  • Centura Health Research Center

    Denver, Colorado

  • George Washington University

    Washington D.C., District of Columbia

  • Florida Hospital

    Orlando, Florida

  • Montefiore Medical Center

    The Bronx, New York

  • East Carolina University

    Greenville, North Carolina

  • University of Cincinnati Medical Center

    Cincinnati, Ohio

  • Ohio State University

    Columbus, Ohio

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • Ballad Health

    Johnson City, Tennessee

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee

  • UT Southwestern

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.